Optimized Acute Pain Control With Parecoxib in Uniportal Video-assisted Thoracoscopic Surgery.
CompletedPhase 4NCT05150431
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Chronic pain after thoracic surgery has been a bothering problem since the era of thoracotomy. The prevalence of chronic pain no matter in thoracotomy or video-assisted thoracoscopic surgery is about 30 to 47%. Better acute pain control after thoracic surgery has been assumed to be an effective way for prevention of chronic pain. Especially in this extreme minimal invasive surgery, uniportal video-assisted thoracic surgery, more optimized perioperative analgesics should be found out. In the guideline of "enhanced recovery after surgery", less opioid is suggested. Other than opioids, there are just few parental analgesics could be used, like acetaminophen or cyclooxygenase-2(COX-2) inhibitor. In our study, the investigators would like to build up a better analgesic strategy for uniportal video-assisted thoracoscopic surgery with less opioid and less side effects.
Study details
- Official title
- Perioperative Pain-control With Parecoxib in Uniportal Video-assisted Thoracoscopic Surgery.
- Conditions
- Perioperative Care
- Chronic Post-operative Pain
- Interventions
- Drug: Parecoxib
- Drug: Placebo
- Sponsor
- National Taiwan University Hospital
- Start date
- 2021-12-15
- Primary completion
- 2022-05-01
- Sex
- All
- Age range
- from 20 Years
- Results posted
- No results posted in this snapshot
- Countries
- Taiwan
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * patients who are scheduled for uniportal video-assisted thoracoscopic surgery. * The American Society of Anesthesiology (ASA) score is 1 or 2. Exclusion Criteria: * moderate to severe hepatic or renal insufficiency * active peptic ulcer or gastrointestinal bleeding * allergy to salicylates * pregnancy or lactation period * inflammatory bowel disease * congestive heart failure * accepted coronary artery bypass surgery * ischemic heart disease * peripheral vascular disease * cerebrovascular disease
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05150431